Combination of Oncolytic Virotherapy with Different Antitumor Approaches against Glioblastoma

Int J Mol Sci. 2024 Feb 7;25(4):2042. doi: 10.3390/ijms25042042.

Abstract

Glioblastoma is one of the most malignant and aggressive tumors of the central nervous system. Despite the standard therapy consisting of maximal surgical resection and chemo- and radiotherapy, the median survival of patients with this diagnosis is about 15 months. Oncolytic virus therapy is one of the promising areas for the treatment of malignant neoplasms. In this review, we have focused on emphasizing recent achievements in virotherapy, both as a monotherapy and in combination with other therapeutic schemes to improve survival rate and quality of life among patients with glioblastoma.

Keywords: chemotherapy; combination therapy; glioblastoma; immunotherapy; oncolytic viruses; radiotherapy.

Publication types

  • Review

MeSH terms

  • Glioblastoma* / pathology
  • Humans
  • Oncolytic Virotherapy*
  • Oncolytic Viruses* / genetics
  • Quality of Life